Kovack Advisors, Inc. Acelrx Pharmaceuticals Inc Transaction History

Kovack Advisors, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	BUY	$0.18 - $0.29 $9,000 - $14,499	50,000 New	50,000 $12,000
Q1 2022 May 16, 2022	SELL	$0.28 - $0.61 $17,080 - $37,210	-61,000 Closed	0 $0
Q4 2021 Jan 18, 2022	BUY	$0.49 - $1.02 $7,350 - $15,300	15,000 Added 32.61%	61,000 $34,000
Q3 2021 Nov 03, 2021	BUY	$0.93 - $1.51 $4,650 - $7,550	5,000 Added 12.2%	46,000 $47,000
Q2 2021 Jul 29, 2021	BUY	$1.03 - $1.7 $15,965 - $26,350	15,500 Added 60.78%	41,000 $57,000
Q1 2021 May 04, 2021	BUY	$1.25 - $2.77 $625 - $1,385	500 Added 2.0%	25,500 $43,000
Q4 2020 Jan 14, 2021	BUY	$1.18 - $1.98 $5,900 - $9,900	5,000 Added 25.0%	25,000 $31,000
Q1 2020 Apr 30, 2020	BUY	$0.76 - $2.07 $15,200 - $41,400	20,000 New	20,000 $24,000
Q2 2019 Aug 14, 2019	SELL	$2.1 - $3.93 $21,000 - $39,300	-10,000 Closed	0 $0
Q4 2018 Feb 06, 2019	BUY	$2.13 - $4.8 $21,300 - $48,000	10,000 New	10,000 $23,000
Q3 2018 Oct 09, 2018	SELL	$2.6 - $4.6 $63,421 - $112,207	-24,393 Closed	0 $0
Q2 2018 Aug 01, 2018	BUY	$2.13 - $4.2 $51,957 - $102,450	24,393 New	24,393 $82,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Kovack Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Kovack Advisors, Inc. with notifications on news.